absenc
wellstandard
inhous
fdaapprov
commerci
avail
diagnost
test
reliabl
diagnosi
respiratori
infect
due
mycoplasma
pneumonia
remain
difficult
addit
formal
extern
qualiti
assess
scheme
would
allow
conclud
perform
pneumonia
diagnost
test
exist
review
current
state
knowledg
pneumoniaeassoci
respiratori
infect
context
epidemiolog
studi
publish
past
year
discuss
particular
emphasi
diagnost
strategi
use
impact
result
role
pneumonia
caus
respiratori
tract
infect
rti
differ
studi
studi
due
geograph
epidemiolog
differ
well
applic
differ
diagnost
techniqu
criteria
use
submit
european
journal
clinic
microbiolog
infecti
diseas
electron
supplementari
materi
onlin
version
articl
alreadi
state
proper
valid
standard
nucleic
acid
amplif
techniqu
naat
often
lack
differ
method
use
must
compar
order
defin
sensit
specif
test
similar
exist
serolog
test
new
diagnost
test
well
studi
compar
differ
method
still
remain
undertaken
critic
import
develop
standard
test
clinic
laboratori
mycoplasma
pneumonia
belong
class
mollicut
associ
wide
varieti
acut
chronic
diseas
respiratori
tract
infect
rti
pneumonia
occur
worldwid
age
group
serolog
method
particular
complement
fixat
test
cft
enzym
immunoassay
eia
wide
use
diagnos
pneumonia
infect
applic
polymeras
chain
reaction
pcr
often
accept
rapid
diagnost
test
sinc
cultur
slow
insensit
therapeut
relev
current
avail
naat
extens
valid
cultur
remain
refer
standard
despit
low
sensit
variabl
yield
depend
specimen
test
isol
protocol
use
sensit
naat
almost
alway
superior
tradit
procedur
often
consid
new
gold
standard
howev
differ
studi
use
differ
diagnost
tool
combin
thereof
also
differ
diagnost
criteria
make
diagnosi
infect
therebi
make
comparison
studi
difficult
importantli
lack
standard
result
wide
variat
interlaboratori
test
perform
even
use
test
criteria
effort
standard
diagnost
assay
c
pneumonia
recommend
publish
us
center
diseas
control
prevent
cdc
canadian
laboratori
centr
diseas
control
howev
recommend
exist
standard
diagnost
approach
pneumonia
epidemiolog
pneumoniaeassoci
respiratori
infect
studi
perform
world
purpos
examin
current
state
knowledg
pneumonia
diagnost
sinc
public
minireview
review
vari
popul
studi
diagnost
method
use
studi
publish
lower
respiratori
tract
infect
lrti
associ
found
pneumonia
addit
studi
publish
pneumoniaeassoci
lrti
sinc
data
select
studi
chosen
repres
differ
popul
around
world
summar
tabl
shown
tabl
proport
lrti
children
adult
includ
communityacquir
pneumonia
associ
pneumonia
infect
past
year
rang
vari
age
geograph
locat
popul
examin
diagnost
method
use
lot
studi
diagnosi
pneumonia
base
serolog
alon
use
pcr
assay
alon
least
one
serolog
test
pcr
assay
limit
number
studi
use
cultur
combin
serolog
test
andor
pcr
assay
three
studi
appli
two
differ
pcr
assay
furthermor
high
degre
heterogen
studi
studi
serolog
method
criteria
use
necessarili
interchang
studi
data
present
type
assay
criteria
use
therebi
make
difficult
imposs
compar
result
one
studi
anoth
one
exampl
prospect
studi
incid
etiolog
communityacquir
pneumonia
hospit
adult
patient
publish
research
use
serolog
method
pcr
diagnosi
pneumonia
infect
follow
serolog
criteria
use
rise
seroconvers
iggandor
igmposit
titer
pneumonia
fourteen
percent
patient
thought
serolog
evid
pneumonia
infect
inform
provid
serolog
method
use
furthermor
studi
control
subject
absenc
signific
report
seropreval
patient
group
known
background
rate
seroposit
high
adult
popul
rang
igg
rang
igm
depend
assay
use
anoth
exampl
studi
oosterheert
et
al
random
control
trial
nasopharyng
oropharyng
swab
specimen
patient
admit
antibiot
treatment
lrti
evalu
mean
realtim
pcr
respiratori
virus
atyp
pathogen
well
convent
diagnost
procedur
viru
detect
detail
realtim
pcr
given
although
pneumoniaeposit
patient
result
identifi
method
use
studi
confirm
neg
result
gener
recent
studi
use
pcr
assay
lower
rate
pneumoniaeassoci
lrti
report
studi
use
serolog
test
tabl
commun
outbreak
pneumonia
nilsson
et
al
compar
seminest
realtim
pcr
oropharyng
swab
serolog
diagnosi
pneumonia
infect
differ
time
point
onset
diseas
pneumonia
diagnos
patient
respiratori
tract
infect
fortyf
pcrposit
wherea
signific
rise
igg
titer
igm
antibodi
detect
subject
although
author
found
persist
pneumonia
dna
throat
common
could
present
week
onset
diseas
conclud
pcr
superior
serolog
diagnosi
pneumonia
infect
earli
phase
infect
examin
children
rti
pneumonia
realtim
pcr
two
serolog
assay
passiv
agglutin
test
immunocard
assay
otomo
et
al
confirm
result
nilsson
et
al
found
sensit
specif
pcr
immunocard
assay
respect
accord
author
realtim
pcr
relat
molecular
assay
suitabl
rapid
diagnosi
first
screen
test
data
confirm
lack
correl
serolog
method
cultur
andor
pcr
assay
report
earlier
studi
epidemiolog
data
emerg
pediatr
studi
reveal
similar
inconsist
method
criteria
use
make
diagnosi
acut
pneumonia
infect
tabl
exampl
includ
use
singl
igg
titer
studi
tabl
specif
exampl
small
uncontrol
pediatr
studi
turkey
collect
nasopharyng
sampl
pcr
detect
pneumonia
dna
blood
serolog
first
admiss
hospit
howev
specifi
pcr
test
appli
although
blood
collect
hospit
admiss
serolog
diagnosi
made
accord
materi
method
section
demonstr
increment
igm
greater
increas
igg
enzymelink
immunosorb
assay
elisa
posit
case
definit
mention
either
author
conclud
serolog
test
sensit
specif
pcr
sinc
falseposit
ratio
pcr
anoth
small
uncontrol
pediatr
studi
dalla
texa
identifi
pneumonia
caus
infect
patient
pneumonia
center
appli
elisa
serolog
test
use
increas
igg
singl
igm
titer
evid
acut
infect
howev
specifi
proport
posit
result
differ
antibodi
class
inform
elisa
present
true
role
pneumonia
rti
remain
challeng
given
wide
variat
data
studi
equal
wide
variat
lack
standard
diagnost
method
serolog
measur
specif
antibodi
respons
limit
applic
etiolog
diagnosi
pneumonia
infect
diagnost
result
avail
retrospect
great
number
antigen
prepar
propos
whole
organ
protein
fraction
glycoprotein
fraction
recombin
antigen
commerci
assay
lack
sensit
specif
emphas
need
valid
qualiti
control
sensit
serolog
assay
depend
whether
first
serum
sampl
collect
earli
late
onset
diseas
avail
pair
sera
sinc
accur
diagnosi
made
pair
serum
sampl
requir
rise
titer
appear
three
four
week
onset
diseas
practic
howev
often
one
serum
sampl
acutephas
ill
avail
two
sampl
collect
within
short
time
interv
detect
titer
rise
solitari
high
igg
titer
diagnost
mean
acut
infect
sinc
moment
seroconvers
unknown
necessarili
took
place
time
ill
observ
start
singl
high
titer
cutoff
valu
determin
local
evalu
use
preval
studi
among
popul
group
sinc
igm
antibodi
appear
earlier
igg
antibodi
detect
igm
serum
wide
use
approach
earli
serolog
diagnosi
pneumonia
infect
especi
children
realiz
igm
antibodi
often
produc
children
month
age
proport
primari
infect
reinfect
singl
igm
measur
may
detect
acut
infect
higher
sensit
test
perform
least
day
follow
onset
diseas
patient
igm
antibodi
appear
even
later
ozaki
et
al
found
singl
assay
use
igm
immunocard
meridian
bioscienc
sensit
detect
acut
pneumonia
infect
increas
pair
sera
analyz
seroposit
children
pneumonia
furthermor
elev
igm
may
persist
month
acut
infect
igm
test
usual
less
sensit
specif
chang
antibodi
titer
pair
specimen
separ
sever
week
report
detect
igaspecif
antibodi
seem
good
indic
recent
pneumonia
infect
children
adult
hand
evalu
medac
igm
igg
iga
assay
serum
sampl
patient
acut
rti
narita
find
signific
advantag
detect
iga
children
talkington
et
al
compar
eight
commerci
eia
two
singleus
eia
six
platetyp
eia
detect
specif
igmigg
antibodi
use
pair
serum
sampl
patient
confirm
pneumonia
infect
posit
complement
fixat
test
cft
result
acutephas
sera
rang
immunowel
igmposit
posit
zeu
igg
eia
acutephas
convalesc
phase
serum
sampl
analyz
posit
result
rang
immunowel
igm
assay
posit
remel
iggigm
eia
studi
singleus
eia
prove
reliabl
platetyp
eia
beersma
et
al
evalu
sensit
specif
assay
detect
pneumonia
igm
igg
well
cft
assay
low
sensit
novum
immunocard
igm
best
perform
term
sensit
specif
record
anilab
system
respect
cft
respect
petitjean
et
al
found
similar
igm
sensit
four
pneumonia
test
children
wide
variat
adult
platelia
bmd
biotest
sorin
specif
test
respect
latter
two
igm
test
thu
use
diagnosi
sensit
igg
test
children
vari
sensit
igg
test
adult
compar
compar
four
igm
igg
igaspecif
eia
sera
blood
donor
patient
infect
caus
pneumonia
et
al
report
detect
frequenc
igm
blood
donor
vari
patient
iga
detect
blood
donor
sera
patient
illustr
use
serolog
kit
may
lead
seriou
overdiagnosi
pneumonia
infect
final
nirpaz
et
al
compar
eight
commerci
avail
test
pneumonia
use
singl
sera
healthi
individu
studi
show
age
associ
test
posit
healthi
individu
igm
peak
primari
secondari
school
age
declin
thereaft
igg
rose
progress
adulthood
high
igm
posit
age
group
cast
doubt
suggest
combin
igm
test
amplificationbas
test
pediatr
popul
might
benefit
interassay
agreement
poor
studi
confirm
singl
serum
serolog
unsuit
diagnosi
pneumonia
infect
commerci
avail
test
need
improv
conclus
serolog
test
never
offer
earli
diagnosi
therefor
epidemiolog
diagnost
tool
clinic
signific
serolog
test
igm
igg
defin
studi
patient
document
infect
detail
inform
concern
time
laps
onset
diseas
collect
serum
specimen
known
pneumonia
first
recov
medium
devis
hayflick
pplo
agar
supplement
fresh
yeast
extract
prepar
edward
hors
serum
howev
pneumonia
grow
slowli
cultur
may
requir
week
becom
posit
although
cultur
pneumonia
still
consid
gold
standard
seldomli
perform
diagnost
test
cultur
remain
essenti
biolog
molecular
character
clinic
isol
includ
antibiot
resist
studi
howev
use
routin
diagnost
tool
suboptim
last
year
naat
becom
major
tool
detect
microorgan
diagnost
test
research
purpos
field
infecti
diseas
naat
offer
signific
sensit
speed
compar
cultur
requir
presenc
viabl
organ
diagnost
test
microorgan
base
naat
becom
increasingli
complex
field
chang
expand
rapidli
thu
naat
establish
year
ago
design
best
inform
knowledg
avail
time
may
necessarili
stateoftheart
today
valid
commerci
avail
fdaclear
assay
exist
limit
number
organ
detect
pneumonia
respiratori
specimen
also
number
socal
analytespecif
reagent
commerci
avail
besid
standard
kit
use
naat
research
purpos
kit
inhous
develop
naat
expand
tremend
assay
rang
well
valid
care
read
mani
public
reveal
often
littl
inform
provid
valid
naat
appli
yet
assay
frequent
use
cite
literatur
time
minireview
publish
inhous
naat
detect
pneumonia
dna
rna
howev
valid
primarili
analyt
none
assay
extens
evalu
use
clinic
specimen
welldefin
patient
popul
wide
geograph
area
sinc
addit
assay
describ
tabl
great
variat
method
use
studi
studi
includ
variabl
target
gene
rrna
atpas
gene
pare
gene
tuf
gene
monoplex
versu
multiplex
target
naat
convent
nest
realtim
rna
vs
dna
target
pcr
nucleic
acid
sequencebas
amplif
technolog
detect
format
agaros
gel
electrophoresi
sybr
green
taqman
probe
hybrid
probe
molecular
beacon
microchip
electrophoresi
furthermor
consensu
optim
respiratori
specimen
use
pneumonia
detect
nucleic
acid
amplif
test
cultur
differ
specimen
use
sputum
nasopharyng
oropharyng
swab
wash
bronchoalveolar
lavag
pleural
fluid
review
optim
sampl
detect
respiratori
pathogen
loen
et
al
conclud
sputum
avail
might
best
specimen
pneumonia
detect
cultur
naat
nasopharyng
swab
nasopharyng
aspir
oropharyng
swab
might
second
best
option
analysi
naat
interstudi
variat
relat
refer
diagnost
assay
new
assay
compar
serolog
test
cultur
preexist
pcr
assay
due
lack
conform
differ
studi
difficult
compar
data
studi
studi
winchel
et
al
evalu
three
realtim
pcr
assay
target
atpas
gene
newli
describ
card
toxin
gene
pneumonia
outbreak
total
respiratori
specimen
patient
control
test
triplic
pcr
assay
assay
target
card
toxin
gene
prove
sensit
lower
ctvalu
identifi
posit
specimen
analyt
sensit
assay
cfu
wherea
cfu
two
assay
howev
author
conclud
inclus
second
pcr
assay
may
provid
increas
level
confid
report
result
dumk
jacob
compar
standard
condit
perform
two
commerci
pcr
assay
artu
qiagen
gmbh
hilden
germani
venor
mpqp
pneumonia
kit
minerva
biolab
gmbh
berlin
germani
three
inhous
pcr
assay
detect
pneumonia
lightcycl
roch
diagnost
gmbh
mannheim
germani
five
procedur
abl
demonstr
pneumonia
dna
concentr
compar
differ
mean
cross
point
test
procedur
caus
differ
calcul
mean
concentr
genom
equival
factor
multicent
studi
use
larg
geograph
divers
repertoir
clinic
specimen
compar
data
center
independ
like
provid
import
insight
perform
new
assay
date
two
studi
describ
multicent
comparison
perform
variou
naat
detect
pneumonia
respiratori
specimen
publish
studi
reveal
signific
variat
test
perform
laboratori
laboratori
ursi
et
al
collect
panel
respiratori
sampl
patient
analyz
three
differ
center
presenc
pneumonia
dna
differ
pcr
assay
nucleic
acid
extract
one
site
subsequ
amplifi
three
center
loen
et
al
use
spike
respiratori
specimen
compar
perform
sever
naat
use
laboratori
extract
amplif
protocol
studi
reveal
signific
intercent
discord
detect
rate
use
differ
even
test
despit
fact
laboratori
particip
experienc
use
pcr
assay
spring
pilot
panel
molecular
diagnosi
pneumonia
produc
qualiti
control
molecular
diagnost
qcmd
extern
qualiti
assess
eqa
panel
consist
total
sampl
bronchoalveolar
lavag
bal
transport
medium
prepar
assess
profici
laboratori
correct
detect
chlamydophila
pneumonia
mycoplasma
pneumonia
naat
six
sampl
contain
variou
concentr
inclus
form
unit
ifu
ml
c
pneumonia
five
sampl
contain
variou
concentr
color
chang
unit
ccu
ml
pneumonia
two
sampl
neg
seventynin
laboratori
countri
particip
eqa
studi
sixtyseven
dataset
obtain
pneumonia
convent
commerci
convent
inhous
n
realtim
commerci
realtim
inhous
strand
displac
amplif
sda
total
panel
correct
result
per
sampl
vari
pneumonia
respiratori
virus
socal
atyp
bacteria
respons
rti
may
produc
clinic
similar
manifest
order
reduc
cost
handson
time
multiplex
nucleic
acid
amplif
techniqu
mxnaat
develop
tabl
origin
two
three
organ
target
one
assay
current
assay
detect
target
howev
comparison
monoplex
multiplex
assay
rare
perform
find
conclus
result
frequent
contradictori
conflict
data
concern
sensit
specif
mxnaat
compar
monoplex
naat
owe
complex
variabl
multiplex
pcr
includ
differ
combin
primer
concentr
magnesium
ion
concentr
anneal
temperatur
unexpect
result
mxnaat
profici
panel
seem
confirm
multiplex
assay
somewhat
less
sensit
monoplex
assay
number
organ
present
clinic
specimen
diseas
individu
known
imposs
state
whether
degre
sensit
attain
clinic
accept
propos
industryproduc
assay
kit
form
may
enabl
standard
pneumoplex
assay
prodess
inc
tabl
report
sensit
sampl
contain
cfuml
pneumonia
specif
detect
pneumonia
spike
specimen
sensit
chlamyleg
assay
argen
inc
tabl
ccu
per
reaction
tube
pneumonia
cohort
clinic
sampl
patient
document
respiratori
infect
analyz
kit
includ
two
sampl
patient
c
pneumonia
infect
nine
sampl
patient
pneumonia
infect
sampl
patient
legionella
speci
infect
sampl
test
neg
three
pathogen
posit
specimen
correctli
detect
identifi
chlamyleg
kit
falseposit
result
observ
neg
sampl
kit
evalu
pediatr
prospect
studi
includ
endotrach
aspir
result
compar
obtain
three
monoplex
inhous
pcr
assay
six
specimen
found
posit
pneumonia
use
strategi
chlamyleg
kit
detect
two
addit
sampl
posit
pneumonia
compar
analysi
limit
detect
resplex
assay
tabl
realtim
singl
pcr
assay
demonstr
resplex
assay
less
sensit
detect
pneumonia
furthermor
resplex
assay
perform
nasopharyng
swab
specimen
known
posit
realtim
pcr
three
pathogen
c
pneumonia
pneumonia
pneumonia
detect
c
pneumonia
pneumonia
pneumoniaeposit
sampl
respect
howev
sinc
calcul
sensit
industryproduc
multiplex
assay
mainli
depend
dna
copi
number
evalu
standard
use
extend
number
clinic
specimen
may
low
load
organ
need
also
trend
adapt
commerci
avail
eg
microseq
mycoplasma
appli
biosystem
inhous
pcr
assay
screen
cell
cultur
presenc
mollicut
respiratori
specimen
specif
gener
detect
pneumonia
assay
need
extens
valid
term
sensit
specif
well
appli
clinic
respiratori
specimen
ideal
newli
propos
naat
assay
valid
comparison
sensit
cultur
system
least
one
valid
pcr
anoth
naat
assay
target
differ
gene
differ
sequenc
gene
convent
manual
nucleic
acid
extract
isol
pathogen
dna
rna
clinic
sampl
laborintens
critic
part
current
nucleic
acid
diagnost
assay
autom
nucleic
acid
extract
system
high
flexibl
type
number
sampl
handl
wide
rang
sampl
input
elut
volum
short
turnaround
time
improv
applic
naat
clinic
servic
data
literatur
indic
sensit
naat
nucleic
acid
extract
autom
system
similar
better
sensit
manual
nucleic
acid
extract
easymag
nucleic
acid
extractor
appli
retrospect
clinic
specimen
better
amplif
result
obtain
pneumonia
c
pneumonia
detect
compar
manual
method
qiagen
blood
mini
kit
nuclisen
minimag
platform
autom
nucleic
acid
extract
instrument
need
evalu
sinc
report
publish
describ
first
macrolideresist
pneumonia
strain
possess
rrna
gene
mutat
report
follow
although
macrolideresist
strain
detect
japan
far
first
macrolideresist
pneumonia
strain
europ
report
recent
franc
sinc
impact
macrolid
resist
outcom
infect
clear
far
measur
need
taken
identifi
strain
pcr
assay
develop
detect
mutat
assay
target
vdomain
rrna
gene
presenc
point
mutat
amplicon
detect
use
restrict
fragment
length
polymorph
rflp
highresolut
melt
curv
analysi
recent
year
signific
progress
made
microbiolog
diagnosi
mycoplasma
pneumonia
respiratori
tract
infect
rti
despit
mani
effort
much
still
unknown
role
pneumonia
respiratori
infect
mycoplasma
infect
never
microbiolog
diagnosi
rapid
sensit
specif
method
direct
detect
readili
avail
physician
offic
hospit
laboratori
signific
limit
continu
surround
accur
reliabl
serolog
diagnosi
pneumonia
infect
includ
wide
variat
method
diagnost
criteria
use
across
studi
result
subsequ
emerg
data
remain
incompar
often
controversi
discord
time
incorrect
methodolog
use
numer
inhous
pcr
assay
detect
pneumonia
develop
proper
valid
standard
still
often
lack
qualiti
control
studi
reveal
frequent
defici
result
falseneg
falseposit
result
consequ
newli
develop
test
must
submit
extens
valid
introduct
molecular
diagnost
laboratori
valid
must
perform
sever
level
includ
sampl
prepar
amplif
detect
sinc
respiratori
sampl
often
contain
substanc
inhibit
amplif
special
attent
paid
effici
reaction
sampl
test
valid
evalu
profici
test
program
wherea
qualiti
control
essenti
part
qualiti
assur
molecular
diagnost
profici
panel
detect
pneumonia
readili
avail
urgent
need
allow
meaning
comparison
result
obtain
differ
laboratori
conclus
follow
standard
follow
laboratori
valid
new
test
detect
pneumonia
abil
appli
second
pcr
anoth
target
least
case
epidem
situat
ii
perform
profici
test
regularli
blind
fashion
ensur
proper
test
personnel
perform
iii
incorpor
hierarch
accept
criteria
monitor
test
failur
includ
posit
neg
control
reevalu
multipl
consecut
posit
specimen
confirm
posit
specimen
collect
person
meet
clinic
case
definit
furthermor
multicent
studi
use
larg
geograph
divers
repertoir
clinic
specimen
compar
data
center
independ
like
provid
import
insight
perform
new
assay
given
high
sensit
specif
nucleic
acidamplif
techniqu
naat
naat
prefer
diagnost
procedur
diagnosi
pneumonia
infect
provid
qualiti
procedur
control
addit
prospect
multicent
studi
larg
number
patient
respiratori
sign
symptom
includ
hospit
nonhospit
patient
necessari
extend
knowledg
epidemiolog
pneumonia
